Radium-223 in an Early Access Program: Effects of Concomitant Medication on OS in mCRPC Patients - Thomas Keane

June 15, 2015

Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Thomas E. Keane, MBBCh, FRCSI, FACS
Professor and Chairman of the Department of Urology
Medical University of South Carolina, Charleston, SC USA


Click HERE to view the poster from ASCO 2015

Click HERE to read the ASCO 2015 session highlights, Timing of Radium-223 in Today’s Treatment Landscape


Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.

Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as Cancer Research, The Journal of Urology, Urologic Oncology, and the Journal of Clinical Investigation. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is coeditor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Edition. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.